SGS Life Science Services, a clinical and bioanalytical contract group has invested in additional modules for its COBAS 6000 analysis system, to increase its biomarker analytical capabilities.
The group now has testing capabilities across a number of instrument platforms, for both multiplexing and single analyte testing.
The Roche COBAS system 6000, introduced in June 2014 at the SGS facility in Poitiers, France, was initially equipped with the clinical chemistry module for small molecule and analyte testing.
The recent expansion of capabilities involves the addition of an immunoassay module which can be used for the quantification of a large number of cytokines, hormones, and other biomarkers of various disease areas such as oncology, endocrinology, sepsis, anemia and cardiac disease.
“It is important for SGS that we continue to adapt and evolve to meet our clients’ needs in this rapidly changing area of the industry,” commented Alain Renoux, Director of SGS Life Science Services, Poitiers. “By investing in new areas across our global network, both scientifically and geographically, we continue to underpin our commitment to our existing clients and increase our appeal to new markets.”